Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02886065
Title A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

smoldering myeloma

Therapies

Durvalumab

Durvalumab + PVX-410

Durvalumab + Lenalidomide + PVX-410

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.